
Full INTerpath-001 results show the individualized mRNA therapy plus pembrolizumab reduced recurrence risk in resected stage IIB-IV melanoma.
The American Journal of Managed Care
about 29 years ago
Migraine: A Problem for Employers and Managed Care Plansabout 29 years ago
Travel Medicine: Considerations for the Primary Care Physician





